Journal
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
Volume 27, Issue 2, Pages 175-185Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2014.07.011
Keywords
myelofibrosis; anaemia; myeloproliferative neoplasm; anaemia treatment
Categories
Ask authors/readers for more resources
Anaemia is a common finding at diagnosis in myelofibrosis, and becomes a symptomatic problem in most patients with time. There are several treatment options for specific anaemia treatment, none of which has been tested in large, randomized, controlled trials. However, as myelofibrosis is not a disease with spontaneous remissions, even non-randomized trials carry weight In this survey, the existing evidence will be analysed, both for the commonly used treatments like erythropoiesis-stimulating agents, androgens and thalidomide and for the new drugs in the area, and conclusions will be drawn concerning standard clinical anaemia treatment in myelofibrosis, which according to evidence from studies has a 40-50% chance of response in patients with not too advanced disease. (C) 2014 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available